Histamine mediates behavioural and metabolic effects of 3-iodothyroacetic acid, an endogenous end product of thyroid hormone metabolism

British Journal of Pharmacology

Volumn 171, Issue 14, 2014, Pages 3476-3484

  Musilli, Claudia ^a   De Siena, Gaetano ^a   Manni, Maria Elena ^a   Logli, Andrea ^a   Landucci, Elisa ^a   Zucchi, Riccardo ^b   Saba, Alessandro ^b   Donzelli, Riccardo ^b   Passani, Maria Beatrice ^a   Provensi, Gustavo ^a   Raimondi, Laura ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

3 iodoacetic acid; anti histaminergic drugs; histamine; learning; pain; thyromimetics

Indexed keywords

3 IODOTHYROACETIC ACID; 3 IODOTHYRONAMINE; GLUCOSE; HISTAMINE; HISTAMINE RECEPTOR; HISTIDINE DECARBOXYLASE; MEPYRAMINE; THYROID HORMONE DERIVATIVE; UNCLASSIFIED DRUG; ZOLANTIDINE; 3-IODOTHYROACETIC ACID; THYROID HORMONE; THYRONINE DERIVATIVE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CD-1 MOUSE; CONTROLLED STUDY; EUTHYROIDISM; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOT PLATE TEST; HYPERALGESIA; HYPERGLYCEMIA; LEARNING; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PAIN THRESHOLD; PASSIVE AVOIDANCE; PRIORITY JOURNAL; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; DEFICIENCY; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; BEHAVIOR, ANIMAL; HISTAMINE; HISTIDINE DECARBOXYLASE; MICE; MICE, KNOCKOUT; THYROID HORMONES; THYRONINES;

EID: 84903197470     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12697     Document Type: Article

References (37)

1. Agretti P, De Marco G, Russo L, Saba A, Raffaelli A, Marchini M, et al. (2011). 3-Iodothyronamine metabolism and functional effects in FRTL5 thyroid cells. J Mol Endocrinol 47: 23-32.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al,. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Anaclet C, Parmentier R, Ouk K, Guidon G, Buda C, Sastre JP, et al. (2009). Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. J Neurosci 29: 14423-14438.
5. Chu XP, Papasian CJ, Wang JQ, Xiong ZG, (2011). Modulation of acid-sensing ion channels: molecular mechanisms and therapeutic potential. Int J Physiol Pathophysiol Pharmacol 3: 288-309.
6. Cumero S, Fogolari F, Domenis R, Zucchi R, Mavelli I, Contessi S, (2012). Mitochondrial F(0) F(1)-ATP synthase is a molecular target of 3-iodothyronamine, an endogenous metabolite of thyroid hormone. Br J Pharmacol 166: 2331-2347.
7. Dratman MB, Gordon JT, (1996). Thyroid hormones as neurotransmitters. Thyroid 6: 639-647.
8. Galeotti N, Malmberg-Aiello P, Bartolini A, Schunack W, Ghelardini C, (2004). H1-receptor stimulation induces hyperalgesia through activation of the phospholipase C-PKC pathway. Neuropharmacology 47: 295-303.
9. Galli E, Marchini M, Saba A, Berti S, Tonacchera M, Vitti P, et al. (2012). Detection of 3-iodothyronamine in human patients: a preliminary study. J Clin Endocrinol Metab 97: E69-E74.
10. Guieu R, Harley JR, Blin O, Pouget J, Serratrice G, (1993). Nociceptive threshold in hypothyroid patients. Acta Neurol (Napoli) 15: 183-188.
11. Hackenmueller SA, Scanlan TS, (2012). Identification and quantification of 3-iodothyronamine metabolites in mouse serum using liquid chromatography-tandem mass spectrometry. Endocrinology 1256: 89-97.
12. Haley TJ, McCormick WG, (1957). Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 12: 12-15.
13. Hiramanek N, (2004). Itch: a symptom of occult disease. Aust Fam Physician 33: 495-499.
14. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap B, Strasburger CJ, et al. (2011). Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. J Clin End Metab 96: 1864-1872.
15. Hough LB, Rice FL, (2011). H3 receptors and pain modulation: peripheral, spinal, and brain interactions. J Pharmacol Exp Ther 336: 30-37.
16. Ishibory M, Itoh Y, Oishi R, Saeki K, (1990). Effect of microinjection of histamine into the brain on plasma levels of epinephrine and glucose in freely moving rats. Jpn J Pharmacol 54: 257-263.
17. Jarvik ME, Kopp R, (1967). An improved one-trial passive avoidance learning situation. Psychol Rep 21: 221-224.
18. Köhler CA, da Silva WC, Benetti F, Bonini JS, (2011). Histaminergic mechanisms for modulation of memory systems. Neural Plast 2011: 328602. doi: 10.1155/2011/328602.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
20. Manni ME, Bigagli E, Lodovici M, Zazzeri M, Raimondi L, (2012). The protective effect of losartan in the nephropathy of the diabetic rat includes the control of monoamine oxidase type A activity. Pharmacol Res 65: 465-471.
21. Manni ME, De Siena G, Saba A, Marchini M, Bigagli E, Cinci L, et al. (2012). 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mouse. Br J Pharmacol 166: 650-658.
22. Manni ME, De Siena G, Saba A, Marchini M, Landucci E, Gerace E, et al. (2013). Pharmacological effects of 3-iodothyronamine (TA1M) in mice include facilitation of memory acquisition and retention and reduction of pain threshold. Br J Pharmacol 168: 354-362.
23. Masini-Repiso AM, Bonaterra M, Spitale L, Di Fulvio M, Bonino MI, Coleoni AH, et al. (2004). Ultrastructural localization of thyroid peroxidase, hydrogen peroxide-generating sites, and monoamine oxidase in benign and malignant thyroid diseases. Hum Pathol 35: 436-446.
24. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Metszaros Z, Szombathy T, Raimondi L, Karadi I, Romics L, Magyar K, (1999). Elevated serum levels of semicarbazide-sensntive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride. Metabolism 48: 113-117.
26. Nishibori M, Itoh Y, Oishi R, Saeki K, (1987). Mechanism of the central hyperglycemic action of histamine in mice. J Pharmacol Exp Ther 241: 582-586.
27. Ohtsu H, Tanaka S, Terui T, Hori Y, Makabe-Kobayashi Y, Pejler G, et al. (2001). Mice lacking histidine decarboxylase exhibit abnormal mast cells. FEBS Lett 502: 53-56.
28. Petrovic N, Cvijic G, Djordjevic J, Davidovic V, (2005). The activities of antioxidant enzymes and monoamine oxidase and uncoupling protein 1 content in brown fat of hypo- and hyperthyroid rats. Ann N Y Acad Sci 1040: 431-435.
29. Pino R, Failli P, Mazzetti L, Buffoni F, (1997). Monoamine oxidase and semicarbazide-sensitive amine oxidase activities in isolated cardiomyocytes of spontaneously hypertensive rats. Biochem Mol Med 62: 188-196.
30. Pittman CS, Buck MW, Chambers JB, (1972). Urinary metabolites of 14C-labeled thyroxine in man. J Clin Invest 51: 1759-1766.
31. Rivas M, Naranjo JR, (2007). Thyroid hormones, learning and memory. Genes Brain Behav 6 (Suppl. 1): 40-44. Review.
32. Rush DK, (1988). Scopolamine amnesia of passive avoidance: a deficit of information acquisition. Behav Neural Biol 50: 255-274.
33. Saba A, Chiellini G, Frascarelli S, Marchini M, Ghelardoni S, Raffaelli A, et al. (2010). Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology 151: 5063-5073.
34. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, et al. (2004). 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10: 638-642.
35. Tancevski I, Rudling M, Eller P, (2011). Thyromimetics: a journey from bench to bed-side. Pharmacol Ther 131: 33-39.
36. Wood WJ, Geraci T, Nilsen A, DeBarber AE, Scanlan TS, (2009). Iodothyronamines are oxidatively deaminated to iodothyroacetic acids in vivo. Chembiochem 10: 361-365.
37. Zucchi R, Chiellini G, Scanlan TS, Grandy DK, (2006). Trace amine-associated receptors and their ligands. Br J Pharmacol 149: 967-978.